美国儿童使用20价肺炎球菌结合疫苗的公共卫生影响与成本效果
BACKGROUND: In June 2023, the Advisory Committee on Immunization Practices (ACIP) recommended 20-valent pneumococcal conjugate vaccine (PCV20) as an option for pneumococcal conjugate vaccine (PCV) administration for children in the United States (U.S.).…
要点
- PCV20替换PCV15可减少151460例肺炎球菌病事件和13例死亡。
- 一般风险组每QALY成本153715美元,CMC和IC组总成本节省。
- CMC和IC组中PCV20联合PPSV23较单用PCV20每QALY成本更高。
核心结论
- 美国常规婴儿免疫规划中使用PCV20预计可降低所有风险组的肺炎球菌病临床负担,并在CMC和IC组产生总体成本节省。
研究设计与样本
- 按风险分层为慢性疾病儿童、免疫抑制儿童和一般儿童三组。
- 比较PCV20单用与PCV20联合PPSV23在CMC和IC儿童中的使用。
主要发现
- 基础病例结果显示,所有风险组中使用PCV20替代PCV15估计可避免151460例肺炎球菌病事件和13例相关死亡。
- 与单用PCV20相比,PCV20联合PPSV23每QALY增益成本在IC组为690388美元,在CMC组为4086881美元。
临床怎么用
- 可为ACIP推荐PCV20用于美国儿童提供公共卫生影响与成本效果依据。
- 在CMC和IC儿童中,PCV20的使用可能带来总体成本节省。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In June 2023, the Advisory Committee on Immunization Practices (ACIP) recommended 20-valent pneumococcal conjugate vaccine (PCV20) as an option for pneumococcal conjugate vaccine (PCV) administration for children in the United States (U.S.). To inform the deliberations of ACIP, we estimated the public health impact and cost-effectiveness of recommending PCV20 for U.S. children. METHODS: Using a probabilistic model, we estimated the cost-effectiveness of replacing PCVs in use at the time of the analysis (13-valent PCV [PCV13] or 15-valent PCV [PCV15]), with PCV20 in a single birth cohort of 3.9 million children. Based on differences in pneumococcal vaccine recommendations, we stratified the population into three mutually exclusive risk groups: children with chronic medical conditions (CMC), children with immunocompromising conditions (IC), and children with neither CMC nor IC (general). We also compared the use of PCV20 alone to the use of PCV20 plus the 23-valent polysaccharide vaccine (PPSV23) in CMC and IC children. We computed the incremental cost-effectiveness ratio of PCV20 use as a net cost per quality-adjusted life-year (QALY) gained. RESULTS: Our base case results showed that use of PCV20 instead of PCV15 across all risk groups in one birth cohort was estimated to avert 151,460 pneumococcal disease events and 13 associated deaths. While this resulted in higher costs of $234 million dollars in the general risk group, leading to a cost per QALY of $153,715, it reduced the total costs by $1 million and $0.48 million in the CMC and IC risk groups. Compared with PCV20 alone, PCV20 plus PPSV23 cost $690,388 (IC) to $4,086,881(CMC) per QALY gained. CONCLUSION: Use of PCV20 in the U.S. routine infant immunization program is expected to reduce the clinical burden of pneumococcal disease across all risk groups and specifically yield overall cost savings in the CMC and IC risk groups.
引用
- Ayabina D, Stoecker C, Cho BH, et al. Public health impact and cost-effectiveness of 20-valent pneumococcal conjugate vaccine use among children in the United States. Vaccine. 2026. PMID: 41564611. doi:10.1016/j.vaccine.2026.128212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。